Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTMoby IntelligenceWed, August 5, 2026 at 6:51 PM GMT+2 3 min readAcacia Research Corporation Q2 2026 Earnings Call Summary - MobyStrategic Performance and Operational DriversOur analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.Performance was driven by a diversified model where strong operating company results were bolstered by a significant Wi-Fi 6 licensing settlement.Management emphasizes compounding long-term intrinsic value per share through disciplined capital allocation rather than maximizing short-term earnings.Benchmark's record revenue was supported by the successful commencement of production from the Cherokee development, which performed in line with expectations.Deflecto is undergoing structural manufacturing optimization and restructuring to position the platform for profitable growth as demand improves.The Intellectual Property platform has been aggressively rationalized to align its cost structure with the episodic nature of licensing opportunities.Acacia maintains a debt-free parent company balance sheet, which management views as a critical competitive advantage for executing acquisitions during market dislocations.Strategic Outlook and Acquisition PipelineThe acquisition pipeline remains active, with management focusing on bilateral discussions and acute situations rather than broad, competitive auction processes.Benchmark's strategy prioritizes maximizing long-term value over near-term production, with plans to evaluate additional drilling units using a disciplined underwriting framework.Deflecto is positioned for meaningful operating leverage as market demand recovers, supported by implemented structural cost improvements.Acacia is exploring a potential transaction to gain direct ownership in Mycovia Pharmaceuticals, aiming for greater participation in value creation following upcoming FDA milestones.The company continues to utilize its public securities portfolio as a 'toehold' strategy to deepen diligence on potential strategic acquisition targets.Non-Recurring Items and Risk FactorsRecorded a $3.7 million non-recurring legal expense related to a legacy litigation matter, which management believes is substantially complete and potentially recoverable.Recognized a full write-down of the investment in MalinJ1 due to liquidity issues at Mycovia Pharmaceuticals following an extended FDA readout timeline.Licensing revenue of $60.6 million was subject to significant contractual splits with partners and contingency counsel, particularly as the TP-Link case proceeded late into the court system.Amortization of legacy intangible assets has declined significantly and is expected to remain at a lower run rate through next year.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info